<DOC>
	<DOCNO>NCT00844532</DOCNO>
	<brief_summary>To determine safety efficacy Absolute Pro™ Peripheral Self-Expanding Stent System subject atherosclerotic de novo restenotic lesion native common iliac artery and/or native external iliac artery .</brief_summary>
	<brief_title>Trial Evaluate Safety &amp; Efficacy Absolute Pro™ Peripheral Self-Expanding Stent System Subjects With Atherosclerotic de Novo Restenotic Lesions Native Common Iliac Artery and/or Native External Iliac Artery .</brief_title>
	<detailed_description />
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<criteria>Clinical 1 . Subject must least 18 &lt; 90 year age . 2 . Subject informed nature trial , agree provision , sign informed consent form . 3 . Subject must agree undergo protocolrequired followup examination requirement investigational site . 4 . History symptomatic claudication ( Rutherford Becker Clinical Category 23 ) ischemic rest pain ( Rutherford Becker Clinical Category 4 ) . 5 . Female subject childbearing potential must negative pregnancy test treatment , must nursing time treatment , agree time consent use birth control participation trial include followup 9 month . Angiographic Inclusion Criteria 1 . Up two bilateral de novo restenotic lesion native common iliac artery and/or native external iliac artery may treat ( one per side ) . 2 . Common iliac artery lesion visually estimate ≥50 % stenosis ≤100 % stenosis ( total occlusion ) 3 . External iliac artery lesion visually estimate ≥50 % stenosis ≤99 % stenosis 4 . Lesion length stenosis common external iliac artery visually estimate ≥ 10 mm ≤ 110 mm ( Absolute Pro ) 5 . Lesion length total occlusion common iliac artery visually estimate ≤40 mm 6 . Target vessel reference diameter visually estimate ≥3.6 mm ≤9.1 mm ( Absolute Pro ) 7 . On treatment side ( ) , patent superficial femoral popliteal artery least one patent distal outflow artery inline distal vessel flow foot confirm arteriography . Patent define &lt; 50 % stenosis . 8 . Lesion length stenosis common external iliac artery visually estimate ≥ 10 mm ≤ 50 mm ( Omnilink Elite ) . 9 . Target vessel reference diameter visually estimate ≥ 5.0 mm ≤ 11.0 mm ( Omnilink Elite ) . Clinical Exclusion Criteria 1 . Subject unable walk . 2 . Subject recent major surgery ( last 3 month ) e.g. , abdominal surgery , coronary artery bypass graft surgery , thoracic surgery . 3 . Subject receive , wait list major organ transplant ( heart , lung , kidney , liver ) . 4 . Subject diagnose Rutherford Becker Clinical Category 0 , 1 , 5 , 6 . 5 . Subject ulcer lesion low extremity ( y ) target lesion side ( ) . 6 . Subject elevate serum creatinine &gt; 2.0 mg/dl . 7 . Subject uncontrolled diabetes mellitus ( DM ) ( serum glucose &gt; 400 mg/dl ) . 8 . Subject myocardial infarction ( MI ) ( Qwave NQWMI ) within previous 30 day . 9 . Subject stroke within previous 30 day and/or deficit prior stroke limit subject ability walk . 10 . Subject unstable angina define rest angina ECG change . 11 . Subject groin infection , acute systemic infection currently treatment . 12 . Subject acute thrombophlebitis deep vein thrombosis either extremity . 13 . Subject require planned procedure within 30 day index procedure would necessitate discontinuation aspirin , clopidogrel ticlopidine follow procedure . 14 . Subject medical illness ( e.g. , cancer congestive heart failure ) may cause subject noncompliant protocol requirement , confound data interpretation , associate limited lifeexpectancy ( i.e. , less 2 year ) . 15 . Subject currently participate investigational drug device trial complete primary endpoint followup clinically interfere current trial endpoint . 16 . Subject unable understand unwilling cooperate trial procedure unwilling unable return treatment center followup visit . 17 . If intend stent Absolute Pro , subject know hypersensitivity contraindication nickel , titanium platinum ; subject know hypersensitivity contraindication standard intraprocedure anticoagulant ( ) ; subject sensitivity contrast adequately pretreated medication . 18 . Subject know allergy contraindication aspirin clopidogrel ( Plavix® ) ; allergy contraindication clopidogrel , subject unable tolerate ticlopidine ( Ticlid® ) . 19 . Subject know bleeding disorder hypercoagulable disorder , refuse blood transfusion . 20 . Subject suffer gastrointestinal ( GI ) bleed within 30 day index procedure would interfere antiplatelet therapy . 21 . If intend stent Omnilink Elite , subject know hypersensitivity contraindication cobalt chromium ; subject know hypersensitivity contraindication standard intraprocedure anticoagulant ( ) ; subject sensitivity contrast adequately pretreated medication . 22 . Requirement general anesthesia spinal block procedure . 23 . Presence contralateral limb amputation perform treat nontraumatic disease limb , e.g . atherosclerotic , vascular , neuropathic . 24 . Presence bypass conduit outflow vessel , i.e . SFA , popliteal , anterior tibial , posterior tibial , peroneal , ipsilateral target lesion . 25 . Subject require concomitant percutaneous endovascular procedure another vessel , e.g . coronary . 26 . Target lesion iliac artery previously stented . Angiographic Exclusion Criteria 1 . Subject totally occluded ( 100 % stenosis ) external iliac artery ipsilateral target lesion . 2 . Subject totally occluded ( 100 % stenosis ) outflow artery ( SFA ) ipsilateral target lesion 3 . Target lesion within adjacent aneurysm . 4 . Lesion locate within beyond vessel contains bypass graft . 5 . Lesion ( ) require atherectomy ( ablative device ) facilitate stent delivery . 6 . Subject history aortic revascularization abdominal aortic aneurysm &gt; 3cm . 7 . Lesion extend beyond inguinal ligament . 8 . Subject angiographic evidence thrombus target disease segment vessel unresponsive antithrombotic therapy . 9 . Subject multilevel disease target extremity require staged procedure within 30 day procedure . 10 . On treatment side ( ) , subject without patent superficial femoral popliteal artery least one patent distal outflow artery inline distal vessel flow foot confirm arteriography . Patent define &lt; 50 % stenosis . 11 . Requirement &gt; 1 stent treat full length lesion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Atherosclerosis</keyword>
	<keyword>Peripheral artery disease</keyword>
	<keyword>Peripheral vascular disease</keyword>
	<keyword>PAD</keyword>
	<keyword>Claudication</keyword>
	<keyword>Peripheral Arterial Occlusive Disease</keyword>
	<keyword>Stent</keyword>
	<keyword>PAOD</keyword>
	<keyword>PVD</keyword>
</DOC>